A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy

NCT01720563 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped Change study drug dosage form

Conditions

Cancer-related Fatigue

Interventions

DRUG: Astragalus polysaccharides 500 mg
DRUG: Placebo
PROCEDURE: Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks

Sponsor

PhytoHealth Corporation